RheumNow

#ACR25 Abstr#LB21 Are they novel somatic variants beyond #VEXAS in driving inflammation in undiagnosed SAID?Unbiased enr https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john… Wed, 10/29/2025 […]

#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at

Not all RA meds are equal for the heart. In >10K older adults w/ RA, advanced therapies lowered MACE risk

POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT 52 wks data Deucra 336pts PBO 334pts then crossover wk

POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies) Oral med Good outcomes Safety very good https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg john+RNV2@john…

In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radi https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg john+RNV2@john…

Questions #ACR25 LB20 to Paul Emery on rosnilimab: Fleischmann: could be induction therapy? (Not intent, but could be) C https://pbs.twimg.com/profile_images/1659729373426241536/tnA2hRe4_normal.jpg

Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic bene https://pbs.twimg.com/profile_images/1389468430160510976/sooz0Ud3_normal.jpg

Upadacitinib: revisiting safety data in RA and GCA mrinalini.dey@… Wed, 10/29/2025 – 08:23

IgG4: Rare, but new treatments on the horizon Janet.Pope@sjh… Wed, 10/29/2025 – 08:39

Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO @Janetbirdope pearls in rheumatology. Sero negative infl https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025 – 07:25 NoufAhmedAlham2

Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl The analogy used by @RheumNow to explain differe https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025

What’s the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john…

Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj @synovialjoints Elaborate more on head to head trial in https://pbs.twimg.com/profile_images/1974180952390721536/r5ej4z9M_normal.jpg john+RNV2@john… Wed, 10/29/2025 –

#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11 https://pbs.twimg.com/profile_images/1625445768768135171/M24lCgC__normal.jpg john+RNV2@john… Wed, 10/29/2025 –

#ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved

#ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ peop

Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but

Can we catch PsA before it starts? My take on #ABSTRACT0877 for #ACR25 @RheumNow https://t.co/Rw2gJ4XSsz https://pbs.twimg.com/profile_images/1800478984926334976/yyyPLP4A_normal.jpg john+RNV2@john… Tue, 10/28/2025 –

Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females – ⬆️discontinuation risks for TNFi 🔅No https://pbs.twimg.com/profile_images/1027501556868870145/2culK0bN_normal.jpg john+RNV2@john…

What a conference! Thanks to all those who stopped by! #ACR25 https://t.co/UMAqnPdK4t https://pbs.twimg.com/profile_images/1915149062988271616/2m4z_QPt_normal.jpg john+RNV2@john… Tue, 10/28/2025 – 20:31 RheumNow Dr.

Sleep Apnea in Psoriatic Arthritis – A Wake Up Call Fatigue is one of the most disabling symptoms in psoriatic